Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes

Grants

Funding Acknowledgements

The original phase III trials were funded by Eisai Inc. The authors would like to thank Cathy O'Brien, Eisai Ltd, Hatfield, UK, for her assistance with the execution of the analyses, with funding from Eisai Inc. Editorial support, provided by Hannah FitzGibbon of Complete Medical Communications, was also funded by Eisai Inc.